Principle LTC, operator of 45 nursing homes in the Southeast, is building on its successful role testing a key drug for COVID-19 prevention and treatment to facilitate trials of a new Alzheimer drug. The goal is to bring staff, resident families and residents without an Alzheimer’s diagnosis into the clinical trial process, improve access to the treatment and build the nursing homes’ reputations in the communities they serve.
Join McKnight’s Long-Term Care News senior editor Kimberly Marselas for this engaging conversation with Principle CEO Lynn Hood, Principle COO Joylin Nation and Tyler Miller of Care Access to learn what it takes to make a drug trial partnership work — and why the success of such initiatives matters not just for trial participants but for the nursing home industry as a whole.
Listen below, then come back to read more about the initiative.
